Full-Time

Validation Specialist 3

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

No salary listed

Albuquerque, NM, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Data Analysis

Get referred to Curia

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Computer Engineering, Physical Sciences, or relevant field of study
  • Minimum of five (5) years validation related work experience
  • Knowledge of regulatory requirements, including FDA regulations, ISO 9000-3, PIC/S guidelines for cGMP, and GAMP 4 and 5 based on the GAMP V-Model Framework, as well as EU GMP Annex 11 for computer systems compliance
  • Must pass a background check
  • Must pass a drug screen
  • May be required to pass Occupational Health Screening
  • Must obtain and maintain gowning certification
  • May be required to obtain and maintain media qualification
Responsibilities
  • Lead the development, execution, and review of complex validation protocols, including computer system validation, manufacturing equipment qualification, packaging equipment validation, and lyophilizer qualification
  • Author, maintain, and approve comprehensive validation master plans ensuring full compliance with regulatory requirements and industry standards such as FDA, cGMP, GAMP, and EU GMP Annex 11
  • Oversee and conduct validation testing activities, analyze data for accuracy, reliability, and compliance, and prepare detailed final reports with recommendations for adjustments or corrective actions
  • Lead cross-functional collaboration to coordinate and integrate validation activities with production and quality teams, ensuring projects meet timelines with minimal disruption
  • Provide expert technical guidance and mentorship on new equipment installations, system modifications, and validation best practices to junior and mid-level validation staff
  • Drive continuous improvement initiatives focused on enhancing validation processes, procedures, and documentation standards
  • Manage relationships with external vendors and consultants to support validation projects and ensure adherence to quality and compliance standards
  • Support regulatory inspections and audits by preparing documentation, responding to inquiries, and addressing validation-related observations
  • Develop and deliver technical training and support to personnel on validation methodologies, regulatory expectations, and quality standards
  • Participate in special projects and perform additional duties as assigned by management to support departmental goals and organizational objectives
  • Read/interpret SOPs to ensure compliance
  • Maintain up to date trainings
  • Other duties as assigned

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Albuquerque’s $200 million expansion adds commercial drug-product capacity during 2025-2026.
  • Glasgow’s upgrade reaches early 2027, expanding batches to 20,000 vials.
  • March 2025 refinancing and July 2026 recapitalization inject capital for near-term execution.

What critics are saying

  • Apollo-led recapitalization on July 8, 2026 signals strained leverage and lender control.
  • Curia will close Burlington by June 1, 2026, cutting 81 jobs and shrinking capacity.
  • Octus reported June 2, 2026 out-of-court restructuring talks; a failed process risks insolvency.

What makes Curia unique

  • Curia spans discovery through commercial fill-finish across 20+ sites, rare among CDMOs.
  • Glasgow and Albuquerque expansions deepen sterile injectables capacity, including Annex 1 isolator lines.
  • Hopkinton CLD upgrades deliver sixfold higher titers, strengthening biologics process-development economics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.